Collaborative Stage

Note 1: Assessment of blood tumor burden is performed using two types of tests: 1) Using the microscope to count neoplastic (Sezary) cells. The results can be given as counts per millimeter cubed (mm3) or as a percentage of the total lymphocytes that are abnormal (Sezary cells). 2) Flow cytometry to characterize the cell surface markers on the neoplastic cells, where the neoplastic cells show the loss of some specific markers (CD26, for example.) Interpretation of the test results is complicated and may vary. In addition, clonality may be assessed as explained in Note 3. The categories are B0 (no significant blood involvement); B1 (low blood tumor burden); and B2 (high blood tumor burden).
Note 2: Record the B rating as stated by the physician. If counts or percentages of neoplastic cells, flow cytometry test results, and/or clonality test results are performed but a B rating is not stated by the physician, use the appropriate code in the series.
Note 3: Clonality may be assessed on tissue and blood samples for this disease. The tests look for what is called "TCR gene rearrangement," a detectable genetic pattern of the T-cell receptors on the neoplastic T-cells. A finding of "monoclonal" means the cells have derived from a single ancestor cell. In this staging system, "monoclonal" is termed "clone +" or "clone positive," and this generally indicates a worse prognosis. "Polyclonal" means the cells in question have not derived from a single ancestor cell, and this finding is termed "clone -" or "clone negative." This may indicate a better prognosis. Tests methods for clonality include Southern blot and PCR (polymerase chain reaction).

Code	Description	B Map
000	No peripheral blood involvement: Less than 1000 Sezary cells	B0
001	OBSOLETE DATA RETAINED V0200 Atypical circulating cells in peripheral blood: Less than 5% Greater than or equal to 1000 Sezary cells	BX
002	OBSOLETE DATA RETAINED V0200 Atypical circulating cells in peripheral blood: Greater than 5%	BX
003	OBSOLETE DATA RETAINED V0200 % Not stated	BX
010	Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary) cells Clone negative Stated B0a	B0a
020	Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary) cells Clone positive Stated B0b	B0b
030	Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary) cells Clone unknown Stated B0 [NOS]	B0NOS
040	Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2 Clone negative Stated as B1a	B1a
050	Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2 Clone positive Stated as B1b	B1b
060	Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2 Clone unknown Stated as B1 [NOS]	B1NOS
070	High blood tumor burden: 1000/uL Sezary cells or more with positive clone Stated as B2	B2
080	% of atypical peripheral blood lymphocytes not stated and B rating not stated	BX
090	Sezary cell counts, blood flow cytometry, and/or clonality results in chart, B rating not stated	BX
100	Sezary cell counts, blood flow cytometry, and/or clonality tests ordered, test results not in chart , B rating not known	BX
999	Insufficient information Not documented in patient record	BX

MycosisFungoides

CS Site-Specific Factor 1
Peripheral Blood Involvement

MycosisFungoides

CS Site-Specific Factor 1Peripheral Blood Involvement

CS Site-Specific Factor 1
Peripheral Blood Involvement